

Appl. No. 09/929,863
Amdt. Dated August 21, 2003
Reply to Office action of March 12, 2003

IN THE CLAIMS:

Claim 1. (Currently amended) A method to induce differentiation of ~~a~~ an isolated or purified naïve CD4⁺ T cell to a Tr1 cell comprising contacting the naïve CD4⁺ T cell with an appropriate amount of interferon- α (IFN- α) and an appropriate amount of IL-10.

Claim 2. (Currently amended) The method of Claim 1, wherein said Tr1 cell is characterized by:

- a) CD4 expression;
- b) high levels of IL-10 production;
- c) significant levels of TGF- β or IFN- γ production; and
- d) little or no production of IL-4 or IL-2.

Claim 3. (Currently amended) The method of Claim 2, wherein:

- a) ~~said high level of the~~ IL-10 production is at least 6000 pg in 1 ml for ~~10⁶ cells~~ in 48 h;
- b) ~~said significant level of the~~ TGF- β production is at least ~~600~~ 100 pg in 1 ml for ~~10⁶ cells in 48 h;~~
- c) ~~said significant level of the~~ IFN- γ production is at least ~~1000~~ 400 pg in 1 ml for ~~10⁶ cells in 48 h;~~
- d) ~~said little or no the~~ IL-4 production is less than 200 pg in 1 ml for ~~10⁶ cell in~~ 48 h; or
- e) ~~said little or no the~~ IL-2 production is less than 200 pg in 1 ml for ~~10⁶ cell in~~ 48 h;

when evaluated from cultures of about 10⁶ cells per ml per 48 hours.

Appl. No. 09/929,863
Amdt. Dated August 21, 2003
Reply to Office action of March 12, 2003

Claim 4. (Currently amended) The method of Claim 2, wherein:

- a) ~~said high level of the~~ IL-10 production is at least ~~6000~~ 12000 pg in 1 ml for ~~10⁶ cells in 48 h;~~
- b) ~~said significant level of the~~ TGF- β production is at least 600 pg in 1 ml for ~~10⁶ cells in 48 h;~~
- c) ~~said significant level of the~~ IFN- γ production is at least 1000 pg in 1 ml for ~~10⁶ cells in 48 h;~~
- d) ~~said little or no the~~ IL-4 production is less than ~~200~~ 100 pg in 1 ml for ~~10⁶ cell~~ in 48 h; or
- e) ~~said little or no the~~ IL-2 production is less than ~~200~~ 100 pg in 1 ml for ~~10⁶ cell~~ in 48 h;

when evaluated from cultures of about 10⁶ cells per ml per 48 hours.

Claim 5. (Original) The method of Claim 2, wherein said Tr1 cell:

- a) has a reduced proliferative potential in response to polyclonal activation;
and/or
- b) suppresses response to alloantigens by responder T cells.

Claim 6. (Currently amended) The method of Claim 1, wherein said Tr1 cells cell suppresses antigen-specific activation of a naive autologous T cells cell.

Claim 7. (Original) The method of Claim 5, wherein said suppressed response to alloantigens is mediated by IL-10 and/or TGF- β .

Claims 8-10. (Cancelled).

8
Claim 1/1. (Original) The method of Claim 1, wherein said contacting is in combination with an antigen.

9 8
Claim 1/2. (Original) The method of Claim 1/1, wherein said antigen is an alloantigen.

Appl. No. 09/929,863
Amdt. Dated August 21, 2003
Reply to Office action of March 12, 2003

10
Claim ~~13~~. (Currently amended) The method of Claim 1, wherein said Tr1 ~~cells are~~ cell
is further proliferated in IL-15.

11
Claim ~~14~~. (Currently amended) The method of Claim 1, wherein said Tr1 ~~cells are~~ cell
is further tested for antigen specificity.

Claims 15-18. (Cancelled).

Claim 19. (New) A method to induce differentiation of an isolated or purified cord blood
T cell to a Tr1 cell comprising contacting the cord blood cell with an appropriate amount
of IFN- α .